Can a diabetes drug boost weight loss after bypass surgery?

NCT ID NCT06162715

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot trial tests whether tirzepatide, a drug used for diabetes and weight loss, can help people who still have obesity one year after gastric bypass surgery. Thirty participants will either receive the drug or standard care. The study tracks weight changes and any stomach-related side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Tirzepatide (also known as Zepbound or Mounjaro)

What this could lead to

If it works, this could offer a new option for people who still have obesity after gastric bypass surgery, helping them lose more weight.

What could go wrong

This is a small pilot study with only 30 people, so results may not apply to everyone. Side effects like gastrointestinal symptoms are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

morbid obesity Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37209, United States